IPSC

Century Therapeutics

Fundamental data last updated:April 13, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

Nasdaq

County of HQ

United States

Next Earnings Date

05/21/26

Business Summary

IPSC Century Therapeutics operates in biotechnology, developing advanced cellular therapies derived from induced pluripotent stem cells. The company’s model centers on creating scalable, standardized cell therapy platforms designed to treat severe diseases, generating value through clinical advancement and potential licensing or commercialization partnerships. Its moat, if realized, would stem from proprietary cell engineering platforms and manufacturing know-how that enable repeatable production at scale. Cash generation is currently dependent on capital markets and strategic funding, with long-term economics tied to successful clinical translation and commercialization leverage.

 


Analyze IPSC on TradingView

VALUATION

P/E

-

Market Cap ($M USD)

$404

Forward P/E

-

PEG

-

PRICE TO SALES

1.8

PRICE TO BOOK

2.5

EV / EBITDA

127.6

5-Year Average P/E

Free Cash Flow Yield

DCF Value

Graham Number

Price to FCF

EV to FCF

Earnings Yield

FCF Yield

DIVIDEND

Yield

-

Annual Payout

-

Payout Ratio

-

Consecutive Years of Dividend Growth

0

5-Year Dividend Growth Rate

-

Financial Health & Profitability

Earnings Per Share

-$0.14

Next Year EPS Growth Estimate

-$0.53

Next Year Revenue Growth Estimate

-

Return on Equity (ROE)

-6.00%

FREE CASH FLOW

Operating Margin

-9.60%

Debt-to-Equity

0.3

Piotroski F-Score

2

Altman Z-Score

-0.3

Return on Invested Capital (ROIC)

-8.10%

Current Ratio

6

Quick Ratio

Net Debt to EBITDA

Interest Coverage

Gross Profit margin

FCF PER SHARE

REVENUE PER SHARE

Analyze IPSC on TradingView

Gainseekers Quantitative Analysis

Summary

At a $404M market cap with a Price/Sales of 1.8 and Price/Book of 2.5, the market is pricing IPSC Century Therapeutics like a distressed early-stage biotech rather than a going concern with durable economics. The absence of a Forward P/E combined with an Altman Z-Score of -0.3 signals meaningful financial stress risk and limited earnings visibility, while a Piotroski F-Score of 2 confirms weak underlying fundamentals. Operating Margin at -6.00% and ROIC at -8.10% show value destruction, not value creation. This is not a mispriced growth compounder; it is a balance-sheet-dependent development story with asymmetric risk skewed to the downside unless fundamentals inflect sharply.

AI Exposure / Tech Reliance

As a Biotechnology company, IPSC Century Therapeutics operates in a research-intensive segment where AI-driven drug discovery and data modeling can materially accelerate pipeline development. The Healthcare sector increasingly integrates computational biology, which can compress timelines and reduce trial failure rates. However, given current negative operating metrics, technology leverage alone will not offset capital intensity without clinical execution.

The Bull Case

A speculative value or deep GARP investor could argue that at 1.8x sales and 2.5x book, expectations are already severely compressed relative to long-term optionality. The Current Ratio of 6 suggests strong short-term liquidity, which provides operational runway despite weak profitability metrics. While ROIC sits at -8.10% and Operating Margin at -6.00%, these are not catastrophic relative to many development-stage biotech peers, and the modest TTM Yield of 0.3 adds a marginal capital return signal. If execution improves, the low Piotroski F-Score of 2 leaves significant room for financial quality expansion, which can drive multiple re-rating.

The Bear Case

The bear case is far more concrete. An Altman Z-Score of -0.3 indicates elevated financial distress risk, and a Piotroski F-Score of 2 reflects deteriorating fundamentals across profitability, leverage, and efficiency signals. Operating Margin of -6.00%, ROIC of -8.10%, and negative forward earnings expectations (EPS Next Year (Est.): -$0.14) suggest continued capital burn. Debt/Equity at -9.60% signals balance sheet instability, while Sales Growth Next Year of -$0.53 implies contraction rather than scaling. With no Forward P/E, no PEG, and no clear profitability bridge, this is a high-risk equity reliant on external funding or transformative clinical catalysts.

Market Sentiment & Smart Money

Short Interest %

5.60%

Analyst Consensus

1.5

Average Analyst Price Target

$4.27

Institutional Ownership %

58.70%

1-Year Beta

1.9

Insider Buying % (6 Mo)

12.80%%

Distance to 52-Week High

74.00%

Distance to 52-Week Low

550.00%

EARNINGS SURPRISE %

50-DAY SMA

200-DAY SMA

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.